Compassionate Use of Ubamatamab

Regeneron Pharmaceuticals

Status

Conditions: Renal Medullary Carcinoma (RMC); Epithelioid Sarcoma

Treatments: Drug: ubamatamab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT07502716

R4018-Ubamatamab

Details and patient eligibility

About

Provide Compassionate Use of Ubamatamab

Full description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility will be determined during the application review process.